



(11)

EP 2 982 681 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(51) Int Cl.:
C07K 7/06 ^(2006.01) **A61K 39/00** ^(2006.01)
A61P 35/00 ^(2006.01) **C07K 7/08** ^(2006.01)
C07K 14/00 ^(2006.01)

(48) Corrigendum issued on:
07.11.2018 Bulletin 2018/45

(86) International application number:
PCT/JP2014/059336

(45) Date of publication and mention
of the grant of the patent:
22.08.2018 Bulletin 2018/34

(87) International publication number:
WO 2014/157692 (02.10.2014 Gazette 2014/40)

(21) Application number: **14775899.9**

(22) Date of filing: **28.03.2014**

(54) **WT1-ANTIGEN PEPTIDE CONJUGATE VACCINE**

WT1-ANTIGEN-PEPTID-KONJUGAT-VAKZIN

VACCIN CONJUGUÉ DE PEPTIDE D'ANTIGÈNE WT1

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **29.03.2013 JP 2013072173**
31.07.2013 JP 2013158383

(43) Date of publication of application:
10.02.2016 Bulletin 2016/06

(60) Divisional application:
18188307.5

(73) Proprietors:
• **Sumitomo Dainippon Pharma Co., Ltd.**
Osaka-shi
Osaka 541-8524 (JP)
• **International Institute of Cancer Immunology, Inc.**
Suita-shi, Osaka 564-0053 (JP)

(72) Inventors:
• **LI, Chiang Jia**
Cambridge
Massachusetts 02141 (US)

- **BAN, Hitoshi**
Osaka-shi,
Osaka 554-0022 (JP)
- **NISHIO, Yukihiro**
Osaka-shi,
Osaka 554-0022 (JP)
- **GOTO, Masashi**
Osaka-shi,
Osaka 554-0022 (JP)
- **NISHIHARA, Toshio**
Osaka-shi,
Osaka 554-0022 (JP)
- **TAKANASHI, Yosuke**
Osaka-shi,
Osaka 554-0022 (JP)

(74) Representative: **Vossius & Partner**
Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München (DE)

(56) References cited:
EP-A2- 2 341 142 **WO-A1-00/06602**
WO-A1-2004/063217 **WO-A1-2008/081701**
JP-A- 2002 525 099 **US-A1- 2006 217 297**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 982 681 B8

- GAIGER ALEXANDER ET AL: "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia", BLOOD, vol. 96, no. 4, 15 August 2000 (2000-08-15), pages 1480-1489, XP002761439, ISSN: 0006-4971
- CHANG ET AL.: 'The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism' PROC. NATL. ACAD. SCI. vol. 102, no. 47, 2005, pages 17107 - 17112, XP055287741
- MODUGNO ET AL.: 'MHC-Peptide Binding: Dimers of Cysteine-Containing Nonapeptides Bind with High Affinity to HLA-A2.1 Class I Molecules' JOURNAL OF IMMUNOTHERAPY vol. 20, no. 6, 1997, pages 431 - 436, XP002976492